Zydus Cadila‘s Covid-19 vaccine ZyCoV-D is getting a nod for emergency use in India by this week. Union Health Minister Mansukh Mandaviya in the Rajya Sabha had said, “The government assumes that by October-November, four more Indian pharma companies will start production of vaccines which will help to reach the demand of vaccines, Biological E and Novartis vaccines will also be available in the coming months, and Zydus Cadila will soon get an emergency use permission from the Expert Committee.”

• Tata Power Inks MoU with Asian Development Bank for $4.25 Billion 
• Innovators Facade Shares Skyrocketed 11% on Securing Orders Worth Rs 110 Crore 
• Stocks in Focus: SJVN, Tata Power, Afcons Infrastructure, and Others
• Stocks Under F&O Ban: Adani Enterprises, Aarti Industries, Indraprastha Gas, and Others 
• RBI Defends Currency Moves to Protect Economy

Zydus Cadila had said before that it has appealed for emergency use authorisation (EUA) with the Drug Controller General of India (DCGI) for its vaccine ZyCoV-D. The pharma company has conducted the most extensive clinical trial in India, with over 50 centres. Zydus Cadila’s vaccine will be the sixth coronavirus vaccine approved in India by the drug regulator after Covishield, Covaxin, Sputnik V, Moderna and Johnson & Johnson (J&J).